Godavari Drugs Limited is an India-based company, which is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and its intermediates. The Company is engaged in the business of contract manufacturing, loan license manufacturing, manufacturing and supply of API, drug intermediaries and fine chemicals. It operates through manufacture and sale of API and its intermediates segment. Its manufacturing facilities are located at the Maharashtra Industrial Development Corporation estate at Nanded, Maharashtra, India. The Company's facility has multiple production blocks for API's, drug intermediates and fine chemicals.
GODAVARI DRUGS LTD. Financial Highlights
- Revenue: GODAVARI DRUGS LTD. reported revenue of ₹106.62 crore in FY26 vs ₹114.33 crore in FY25. It showed a decrease of 6.74% on a yearly basis.
- Operating Profit: GODAVARI DRUGS LTD. reported an operating profit of ₹5.06 crore in FY26 vs ₹5.63 crore in FY25. It showed a decrease of 10.12% on a year-on-year basis.
- Net Profit: GODAVARI DRUGS LTD. reported a net profit of ₹4.09 crore in FY26 vs ₹4.38 crore in FY25. It showed a decrease of 6.62% on a yearly basis.
GODAVARI DRUGS LTD. Quarterly Result Highlights
- GODAVARI DRUGS LTD. reported revenue of ₹33.30 crore in Mar 2026, compared with ₹22.20 crore in Dec 2025, representing an increase of 50.00% on a quarter-on-quarter (QoQ) basis.
- GODAVARI DRUGS LTD. reported an operating profit of ₹1.62 crore in Mar 2026, compared with ₹1.02 crore in Dec 2025, representing an increase of 58.82% on a quarter-on-quarter (QoQ) basis.
- GODAVARI DRUGS LTD. reported a profit of ₹1.29 crore in Mar 2026, compared with ₹0.76 crore in Dec 2025, reflecting an increase of 69.74% on a QoQ basis.
- The earnings per share (EPS) of GODAVARI DRUGS LTD. stood at ₹5.82 during Mar 2026.